Key Insights

Highlights

Success Rate

94% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

2.5%

1 terminated out of 40 trials

Success Rate

93.8%

+7.2% vs benchmark

Late-Stage Pipeline

10%

4 trials in Phase 3/4

Results Transparency

47%

7 of 15 completed with results

Key Signals

7 with results94% success

Data Visualizations

Phase Distribution

26Total
Not Applicable (21)
P 2 (1)
P 3 (1)
P 4 (3)

Trial Status

Completed15
Recruiting13
Unknown5
Not Yet Recruiting3
Enrolling By Invitation1
Terminated1

Trial Success Rate

93.8%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (40)

Showing 20 of 20 trials
NCT07734025Not ApplicableNot Yet Recruiting

A Prospective, Multi-centre, Single Arm, Pivotal Clinical Study to Determine the Safety and Effectiveness of Crea Aortic Valve for Use as a Replacement Aortic Heart Valve

NCT07735130Phase 4Not Yet Recruiting

Angiotensin Receptor Blocker After TAVR in Severe Aortic Stenosis With Left Ventricular Hypertrophy (ARBITAR)

NCT07194265Not ApplicableRecruitingPrimary

A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV System

NCT05493657Not ApplicableRecruitingPrimary

Aspirin vs Clopidogrel After TAVR

NCT01586910Not ApplicableActive Not RecruitingPrimary

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

NCT06818006Phase 4Not Yet Recruiting

Application of TAVI at Experienced Interventional Cardiac Centers Without On-site Cardiac Surgery (ATLAS Study)

NCT07193888RecruitingPrimary

Navitor Japan Study

NCT07596394RecruitingPrimary

A Registry to Assess the Efficacy and Safety of Transcatheter Treatment for Aortic Valve Disease at the IRCCS Policlinico San Matteo Foundation in Pavia (Italy).

NCT01675440CompletedPrimary

Safety & Efficacy Study of the Medtronic CoreValve® System-Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Extreme Risk Subjects Who Need Aortic Valve Replacement

NCT07469371Not ApplicableRecruitingPrimary

CLEAR-AS: CT-FFR-Guided Revascularization in Patients With Severe Aortic Stenosis

NCT04206228Phase 2CompletedPrimary

Intravenous Iron Supplement for Iron Deficiency in Patients With Severe Aortic Stenosis

NCT07414342Not ApplicableRecruitingPrimary

Safety and Efficacy of the RENATUS® Transcatheter Aortic Valve System for the Treatment of Severe Aortic Stenosis

NCT06898086Not ApplicableRecruitingPrimary

Transfemoral TAVI With or Without Coronary Angiogram in Patients With Severe Aortic Stenosis (PURE TAVI)

NCT07309029RecruitingPrimary

Pre-Emptive LAVA-ECMO for Complex High-Risk TAVR

NCT07304427CompletedPrimary

Alwide Plus China Post-market Clinical Investigation

NCT06173115Not ApplicableRecruitingPrimary

Comparison of a Single Versus Double Perclose Technique for TAVR

NCT06679517Enrolling By InvitationPrimary

Observational Study Relating to the Long-term Follow-up of Patients with Severe Aortic Stenosis Evaluated for Percutaneous Aortic Valve Replacement (TAVI).

NCT06834828CompletedPrimary

Prevalence of Cusp Asymmetry, Coronary Ostial Eccentricity in Patients Undergoing Trans Catheter Aortic Valve Implantation and Their Impact on Coronary Ostia Overlap Risk Assessment

NCT06477042RecruitingPrimary

Act on Quality of Life in Patients With aortIc Stenosis

NCT03752866Not ApplicableCompleted

CONFIDENCE Registry to Assess Safety and Performance of Portico System to Treat Patients With Severe Aortic Stenosis.

Scroll to load more

Research Network

Activity Timeline